TrialHaematologica2018

Safety and efficacy of second-line bosutinib for chronic phase chronic myeloid leukemia over a five-year period: final results of a phase I/II study.

Carlo Gambacorti-Passerini et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.